naproxen (Naprosyn, Aleve Anaprox)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradename: Naprosyn, Aleve. Naproxen sodium. Tradename Anaprox. Delayed release naproxen. Tradename EC-Naprosyn.

Indications

Contraindications

pregnancy category = b

safety in lactation = -

Dosage

250-500 mg PO BID 275-550 mg PO BID {Anaprox} 375-500 mg PO BID {EC-Naprosyn} Tabs 200, 250, 375, 500 mg. 275, 550 mg {Anaprox} 375, 550 mg {EC-Naprosyn}

Suspension: 125 mg/5 mL.

Pharmacokinetics

elimination via liver

1/2life = 10-20 hours

protein binding = >99 %

elimination by hemodialysis = -

elimination by peritoneal dialysis = -

Monitor

Adverse effects

* NSAIDS may increase salt & water retention

* 10 days of NSAID therapy prior to interstitial nephritis[15]

Drug interactions

Laboratory

Mechanism of action

More general terms

Additional terms

Component of

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
  3. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  4. Clinical Guide to Laboratory Tests, 3rd ed. Teitz ed., W.B. Saunders, 1995
  5. Prescriber's Letter 13(3): 2006 Cytochrome P450 drug interactions Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220233&pb=PRL (subscription needed) http://www.prescribersletter.com
  6. 6.0 6.1 Journal Watch 21(18):143-44, 2001
  7. 7.0 7.1 Journal Watch 25(7):56, 2005
    Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005 Feb 5;365(9458):475-81. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15705456
  8. Prescriber's Letter 17(7): 2010 Recommended Lab Monitoring for Common Medications Liver Function Test Scheduling Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=260704&pb=PRL (subscription needed) http://www.prescribersletter.com
  9. 9.0 9.1 Prescriber's Letter 17(8): 2010 Managing NSAID Risks Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=260810&pb=PRL (subscription needed) http://www.prescribersletter.com
  10. 10.0 10.1 Anzellotti P et al. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: Recommendations to minimize the functional consequences. Arthritis Rheum 2011 Mar; 63:850. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21360514
  11. 11.0 11.1 Bavry AA, Thomas F, Allison M, et al. Nonsteroidal anti-inflammatory drugs and cardiovascular outcomes in women: results from the Women's Health Initiative. Circ Cardiovasc Qual Outcomes. 2014;7:603-610 PMID: https://www.ncbi.nlm.nih.gov/pubmed/25006185
  12. 12.0 12.1 12.2 Dubreuil M, Louie-Gao Q, Peloquin CE, Choi HK, Zhang Y, Neogi T. Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis. Ann Rheum Dis 2018 Aug; 77:1137 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29674321 https://ard.bmj.com/content/77/8/1137
  13. 13.0 13.1 Baccouche K, Alaya Z, Azzabi A et al Minimal-change disease and interstitial nephritis secondary to non-steroidal anti-inflammatory drugs (naproxen). Therapie. 2016 Oct;71(5):515-517. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27203163
  14. 14.0 14.1 Geriatric Review Syllabus, 11th edition (GRS11) Harper GM, Lyons WL, Potter JF (eds) American Geriatrics Society, 2022
  15. 15.0 15.1 NEJM Knowledge+

Database